Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.86
ESALY's Cash to Debt is ranked lower than
65% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ESALY: 0.86 )
Ranked among companies with meaningful Cash to Debt only.
ESALY' s 10-Year Cash to Debt Range
Min: 0.3  Med: 3.96 Max: 3902.8
Current: 0.86
0.3
3902.8
Equity to Asset 0.57
ESALY's Equity to Asset is ranked lower than
58% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ESALY: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
ESALY' s 10-Year Equity to Asset Range
Min: 0.37  Med: 0.60 Max: 0.7
Current: 0.57
0.37
0.7
Interest Coverage 5.79
ESALY's Interest Coverage is ranked lower than
85% of the 370 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 933.44 vs. ESALY: 5.79 )
Ranked among companies with meaningful Interest Coverage only.
ESALY' s 10-Year Interest Coverage Range
Min: 5.79  Med: 28.02 Max: 2966.46
Current: 5.79
5.79
2966.46
F-Score: 6
Z-Score: 4.70
M-Score: -2.57
WACC vs ROIC
5.12%
8.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.76
ESALY's Operating margin (%) is ranked lower than
53% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. ESALY: 6.76 )
Ranked among companies with meaningful Operating margin (%) only.
ESALY' s 10-Year Operating margin (%) Range
Min: 2.42  Med: 14.75 Max: 16.84
Current: 6.76
2.42
16.84
Net-margin (%) 8.81
ESALY's Net-margin (%) is ranked higher than
61% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. ESALY: 8.81 )
Ranked among companies with meaningful Net-margin (%) only.
ESALY' s 10-Year Net-margin (%) Range
Min: -2.32  Med: 8.46 Max: 10.55
Current: 8.81
-2.32
10.55
ROE (%) 9.01
ESALY's ROE (%) is ranked higher than
58% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. ESALY: 9.01 )
Ranked among companies with meaningful ROE (%) only.
ESALY' s 10-Year ROE (%) Range
Min: -3.4  Med: 10.93 Max: 16.5
Current: 9.01
-3.4
16.5
ROA (%) 4.98
ESALY's ROA (%) is ranked higher than
58% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. ESALY: 4.98 )
Ranked among companies with meaningful ROA (%) only.
ESALY' s 10-Year ROA (%) Range
Min: -1.78  Med: 5.75 Max: 9.24
Current: 4.98
-1.78
9.24
ROC (Joel Greenblatt) (%) 15.63
ESALY's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. ESALY: 15.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESALY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.99  Med: 30.87 Max: 56.21
Current: 15.63
7.99
56.21
Revenue Growth (3Y)(%) -5.50
ESALY's Revenue Growth (3Y)(%) is ranked lower than
79% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ESALY: -5.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESALY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 6.00 Max: 12
Current: -5.5
0
12
EBITDA Growth (3Y)(%) -22.60
ESALY's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. ESALY: -22.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESALY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 3.20 Max: 45
Current: -22.6
0
45
EPS Growth (3Y)(%) -9.60
ESALY's EPS Growth (3Y)(%) is ranked lower than
67% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. ESALY: -9.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESALY' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.3  Med: 7.10 Max: 53.8
Current: -9.6
-17.3
53.8
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.13
ESALY's P/E(ttm) is ranked lower than
64% of the 469 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.80 vs. ESALY: 47.13 )
Ranked among companies with meaningful P/E(ttm) only.
ESALY' s 10-Year P/E(ttm) Range
Min: 12.4  Med: 21.05 Max: 77.73
Current: 47.13
12.4
77.73
PE(NRI) 48.90
ESALY's PE(NRI) is ranked lower than
64% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.50 vs. ESALY: 48.90 )
Ranked among companies with meaningful PE(NRI) only.
ESALY' s 10-Year PE(NRI) Range
Min: 12.4  Med: 21.05 Max: 77.73
Current: 48.9
12.4
77.73
P/B 3.93
ESALY's P/B is ranked lower than
54% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. ESALY: 3.93 )
Ranked among companies with meaningful P/B only.
ESALY' s 10-Year P/B Range
Min: 1.76  Med: 2.27 Max: 4.2
Current: 3.93
1.76
4.2
P/S 4.30
ESALY's P/S is ranked lower than
56% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. ESALY: 4.30 )
Ranked among companies with meaningful P/S only.
ESALY' s 10-Year P/S Range
Min: 0.96  Med: 1.58 Max: 6.6
Current: 4.3
0.96
6.6
PFCF 40.75
ESALY's PFCF is ranked higher than
52% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. ESALY: 40.75 )
Ranked among companies with meaningful PFCF only.
ESALY' s 10-Year PFCF Range
Min: 5.75  Med: 17.24 Max: 50.18
Current: 40.75
5.75
50.18
POCF 30.89
ESALY's POCF is ranked lower than
53% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. ESALY: 30.89 )
Ranked among companies with meaningful POCF only.
ESALY' s 10-Year POCF Range
Min: 4.92  Med: 11.49 Max: 33.01
Current: 30.89
4.92
33.01
EV-to-EBIT 58.05
ESALY's EV-to-EBIT is ranked lower than
74% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. ESALY: 58.05 )
Ranked among companies with meaningful EV-to-EBIT only.
ESALY' s 10-Year EV-to-EBIT Range
Min: 9.2  Med: 13.80 Max: 66.2
Current: 58.05
9.2
66.2
Shiller P/E 45.49
ESALY's Shiller P/E is ranked lower than
58% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.23 vs. ESALY: 45.49 )
Ranked among companies with meaningful Shiller P/E only.
ESALY' s 10-Year Shiller P/E Range
Min: 15.93  Med: 21.89 Max: 48.61
Current: 45.49
15.93
48.61
Current Ratio 2.27
ESALY's Current Ratio is ranked higher than
50% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ESALY: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ESALY' s 10-Year Current Ratio Range
Min: 0.77  Med: 2.29 Max: 3.23
Current: 2.27
0.77
3.23
Quick Ratio 1.85
ESALY's Quick Ratio is ranked higher than
53% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ESALY: 1.85 )
Ranked among companies with meaningful Quick Ratio only.
ESALY' s 10-Year Quick Ratio Range
Min: 0.66  Med: 2.00 Max: 2.87
Current: 1.85
0.66
2.87
Days Inventory 166.33
ESALY's Days Inventory is ranked lower than
73% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. ESALY: 166.33 )
Ranked among companies with meaningful Days Inventory only.
ESALY' s 10-Year Days Inventory Range
Min: 121.01  Med: 149.96 Max: 170.66
Current: 166.33
121.01
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
ESALY's Dividend Yield is ranked higher than
67% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. ESALY: 1.90 )
Ranked among companies with meaningful Dividend Yield only.
ESALY' s 10-Year Dividend Yield Range
Min: 1.58  Med: 4.16 Max: 5.42
Current: 1.9
1.58
5.42
Dividend Payout 0.96
ESALY's Dividend Payout is ranked lower than
89% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. ESALY: 0.96 )
Ranked among companies with meaningful Dividend Payout only.
ESALY' s 10-Year Dividend Payout Range
Min: 0.21  Med: 0.57 Max: 1.12
Current: 0.96
0.21
1.12
Yield on cost (5-Year) 1.90
ESALY's Yield on cost (5-Year) is ranked higher than
62% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. ESALY: 1.90 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ESALY' s 10-Year Yield on cost (5-Year) Range
Min: 1.58  Med: 4.16 Max: 5.42
Current: 1.9
1.58
5.42
Share Buyback Rate -0.10
ESALY's Share Buyback Rate is ranked higher than
76% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.40 vs. ESALY: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
ESALY' s 10-Year Share Buyback Rate Range
Min: 0  Med: 0.00 Max: -0.1
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 88.05
ESALY's Price/Net Current Asset Value is ranked lower than
99% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. ESALY: 88.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ESALY' s 10-Year Price/Net Current Asset Value Range
Min: 4.45  Med: 7.36 Max: 124.02
Current: 88.05
4.45
124.02
Price/Tangible Book 7.67
ESALY's Price/Tangible Book is ranked lower than
74% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. ESALY: 7.67 )
Ranked among companies with meaningful Price/Tangible Book only.
ESALY' s 10-Year Price/Tangible Book Range
Min: 1.74  Med: 3.91 Max: 31.78
Current: 7.67
1.74
31.78
Price/Projected FCF 1.69
ESALY's Price/Projected FCF is ranked higher than
60% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. ESALY: 1.69 )
Ranked among companies with meaningful Price/Projected FCF only.
ESALY' s 10-Year Price/Projected FCF Range
Min: 0.72  Med: 1.05 Max: 2.11
Current: 1.69
0.72
2.11
Price/Median PS Value 2.23
ESALY's Price/Median PS Value is ranked lower than
84% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. ESALY: 2.23 )
Ranked among companies with meaningful Price/Median PS Value only.
ESALY' s 10-Year Price/Median PS Value Range
Min: 0.68  Med: 0.92 Max: 2.71
Current: 2.23
0.68
2.71
Price/Graham Number 3.86
ESALY's Price/Graham Number is ranked lower than
71% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.75 vs. ESALY: 3.86 )
Ranked among companies with meaningful Price/Graham Number only.
ESALY' s 10-Year Price/Graham Number Range
Min: 1.1  Med: 1.89 Max: 4.6
Current: 3.86
1.1
4.6
Earnings Yield (Greenblatt) (%) 1.77
ESALY's Earnings Yield (Greenblatt) (%) is ranked higher than
50% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ESALY: 1.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESALY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.5  Med: 7.30 Max: 10.9
Current: 1.77
1.5
10.9
Forward Rate of Return (Yacktman) (%) -9.43
ESALY's Forward Rate of Return (Yacktman) (%) is ranked lower than
81% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. ESALY: -9.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESALY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -9.5  Med: 6.80 Max: 18.4
Current: -9.43
-9.5
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4523.Japan, EII.Germany,
Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for... Jun 26 2015
Eisai Signs Global IT Outsourcing Contract With Accenture Jun 24 2015
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary... Jun 22 2015
Eisai Receives European Commission Approval of Anticancer Agent Lenvima for Treatment of Advanced... Jun 01 2015
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human... May 29 2015
Eisai Receives Positive CHMP Opinion on Indication Expansion for Antiepileptic Agent Fycompa... May 27 2015
First In Class Fycompa® (Perampanel) Receives Positive CHMP Opinion for Primary Generalised... May 26 2015
Eisai to Promote Clinical Trial Data Disclosure for The Advancement of Science and Medicine May 21 2015
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment... May 20 2015
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting May 14 2015
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog Apr 13 2015
Merck Inks Deal with Syndax for Cancer Combo Therapy - Analyst Blog Apr 01 2015
Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog Mar 13 2015
Eisai Confirms Life-extending Breast Cancer Treatment Halaven® (Eribulin) to Remain on Cancer Drugs... Mar 10 2015
Merck Inks Deal with Eisai for Cancer Combo Therapy - Analyst Blog Mar 06 2015
Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 03 2015
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog Feb 27 2015
Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog Feb 25 2015
Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog Feb 25 2015
Eisai Aghast at NHS England Decision to Remove Life Extending Breast Cancer Treatment From Cancer... Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK